| Literature DB >> 34912214 |
Dan Wang1, Yicheng Liu2, Dandan Tang1, Shujun Wei1, Jiayi Sun1, Lvqiang Ruan2, Lin He1, Ruolan Li1, Qiang Ren3, Xiaoping Tian1, Yunhui Chen1.
Abstract
The Buxue Tongluo pill (BTP) is a self-made pill with the functions of nourishing blood, promoting blood circulation, dredging collaterals, and relieving pain. It consists of Angelica sinensis (Oliv.) Diels, Pheretima aspergillum (E.Perrier), Panax notoginseng (Burk.) F. H. Chen, Astragalus membranaceus (Fisch.) Bge, and Glycyrrhiza uralensis Fisch. Various clinical practices have confirmed the therapeutic effect of BTP on osteonecrosis of the femoral head (ONFH), but little attention has been paid to the study of its bioactive ingredients and related mechanisms of action. In this study, UPLC/MS-MS combined with GEO data mining was used to construct a bioactive ingredient library of BTP and a differentially expressed gene (DEG) library for ONFH. Subsequently, Cytoscape (3.7.2) software was used to analyze the protein-protein interaction between BTP and DEGs of ONFH to screen the key targets, and functional annotation analysis and pathway enrichment analysis were carried out. Finally, 34 bioactive compounds were screened, which acted on 1,232 targets. A total of 178 DEGs were collected, and 17 key genes were obtained after two screenings. By bioinformatics annotation on these key genes, a total of 354 gene ontology (GO) functional annotation analyses and 42 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were obtained. The present study found that GO and KEGG enrichment were mainly related to apoptosis, suggesting that BTP may exert an anti-ONFH effect by promoting osteoclast apoptosis. Experiments in vitro demonstrated that BTP could increase the mitochondrial membrane potential (MMP) and induce remarkable apoptosis in osteoclasts. Furthermore, we determined the apoptosis marker of cleaved(C)-caspase-3, bcl-2, and bax and found that BTP could upregulate the C-caspase-3 and bax expression in osteoclasts and decrease the expression of bcl-2, p-Akt, and p-PI3K in a dose-dependent manner, indicating that BTP could induce PI3K/Akt-mediated apoptosis in osteoclasts to treat ONFH. This study explored the pharmacodynamic basis and mechanism of BTP against ONFH from the perspective of systemic pharmacology, laying a foundation for further elucidating the therapeutic effects of BTP against ONFH.Entities:
Keywords: GEO database; PI3K/AKT; apoptosis; buxue tongluo pill; osteonecrosis of the femoral head
Year: 2021 PMID: 34912214 PMCID: PMC8667870 DOI: 10.3389/fphar.2021.729909
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
FIGURE 1Whole experiment process in our study.
Detailed attribute values of core targets.
| Name | Degree | Betweenness | Closeness |
|---|---|---|---|
| TP53 | 417 | 8838.351 | 0.625 |
| EGFR | 413 | 4978.824 | 0.584532 |
| ESR1 | 362 | 4732.667 | 0.595238 |
| YWHAZ | 354 | 5282.821 | 0.602968 |
| FN1 | 401 | 5764.932 | 0.616114 |
| UBC | 421 | 7284.354 | 0.608614 |
| NTRK1 | 715 | 15501.89 | 0.680628 |
| CUL3 | 519 | 8497.666 | 0.643564 |
| CUL1 | 331 | 4143.496 | 0.604651 |
| CDK2 | 352 | 5856.056 | 0.605778 |
| COPS5 | 364 | 4224.348 | 0.605214 |
| HSP90AB1 | 304 | 3368.986 | 0.577265 |
| ITGA4 | 298 | 3802.689 | 0.592525 |
| HSP90AA1 | 368 | 3823.474 | 0.587703 |
| VCP | 301 | 3662.213 | 0.579839 |
| NPM1 | 291 | 3407.6 | 0.590909 |
| MCM2 | 403 | 6534.106 | 0.617871 |
FIGURE 3Volcano plot (left) and heatmap (right) of differentially expressed genes (DEGs) in microarray data sets of GSE123568 (A). Intersection PPI network of BTP and DEGs. (B) Identification process of core targets of BTP against ONFH. Nodes for genes and edges for interactions between proteins (C).
FIGURE 4Functional enrichment of the core targets of BTP-DEGs. (A) GO enrichment. (B) KEGG enrichment. (C) Network of Key Targets-Pathway. (D) Pathway map of key targets.
FIGURE 5Cytotoxic effect of BTP on RAW264.7 cells. (A) Cell viability assays of RAW 264.7 cells treated with series doses of BTP at 24, 48, and 72 h, respectively. (B) Representative figures of RAW264.7 cells treated with series doses of BTP for 24 h.
Precursor and product ions of constituents in the Buxue Tongluo Pill.
| No. | Compound | RT | Formula | MS1 | MS2 | Herbal medicine | Ref. |
|---|---|---|---|---|---|---|---|
| 1 |
| 1.19 | C6H14N4O2 | 175 [M + H]+ | 116, 71, 70, 60 |
| ( |
| 2 | Asparagine | 1.23 | C4H8N2O3 | 131 [M-H]- | 114, 113, 95, 72 |
| ( |
| 3 | Choline | 1.24 | C5H13NO | 104 [M + H]+ | 60 |
| ( |
| 4 | Sucrose | 1.25 | C12H22O11 | 729 [2M + FA-H]- | 683.625, 387.11475, 179.89 |
| ( |
| 5 | Adenine | 1.26 | C5H5N5 | 136 [M + H]+ | 119, 109 |
| ( |
| 6 | Guanine | 1.33 | C5H5N5O | 152 [M + H]+ | 135, 110, 81, 55 |
| ( |
| 7 | Guanosine | 1.33 | C10H13N5O5 | 284 [M + H]+ | 152, 135,110 |
| ( |
| 8 | Hypoxanthine | 1.34 | C5H4N4O | 137 [M + H]+ | 119, 110 |
| ( |
| 9 | Nicotinic acid | 1.37 | C6H5NO2 | 124 [M-H]- | 96, 80, 78, 52 |
| ( |
| 10 | Phenylalanine | 1.41 | C9H11NO2 | 166 [M + H]+ | 120, 103 |
| ( |
| 11 | Succinic acid | 1.46 | C4H6O4 | 117 [M-H]− | 99, 73 |
| ( |
| 12 | Tryptophan | 2.44 | C11H12N2O2 | 205 [M + H]+ | 188, 170, 159, 142, 132, 130, 118 |
| ( |
| 13 | Caffeic acid | 3.01 | C9H8O4 | 179 [M-H]− | 135 |
| ( |
| 14 | Benzoic acid | 5.19 | C7H6O2 | 121 [M-H]− | 93 |
| ( |
| 15 | 3-Coumaric acid | 6.47 | C9H8O3 | 163 [M-H]- | 119, 93 |
| ( |
| 16 | Calycosin-7-O-β-D-glucoside | 7.37 | C22H22O10 | 447 [M + Na]+ | 285, 270 |
| ( |
| 17 | Chlorogenic acid | 8.08 | C16H18O9 | 355.10 [M + H]+ | 191, 179, 173 |
| ( |
| 18 | Liquiritin | 8.12 | C21H22O9 | 417 [M-H]- | 255, 135, 119 |
| [Meng et al., 2010] |
| 19 | Ferulic acid | 13.24 | C10H10O4 | 195 [M + H]+ | 177, 145 |
| ( |
| 20 | Isoliquiritin | 14.99 | C21H22O9 | 419 [M + H]+ | 257, 147, 137 |
| ( |
| 21 | Daidzein | 15.31 | C15H10O4 | 255 [M + H]+ | 137.91 |
| [Meng et al., 2010] |
| 22 | Ononin | 17.11 | C22H22O9 | 431 [M + H]+ | 268 |
| ( |
| 23 | Formononetin | 17.34 | C16H12O4 | 269 [M + H]+ | 254, 237,137 |
| ( |
| 24 | Ginsenoside Re | 17.41 | C48H82O18 | 991 [M-H]- | 789, 441 |
| ( |
| 25 | Biochanin A | 19.06 | C16H12O5 | 285 [M + H]+ | 270, 253 |
| ( |
| 26 | Licoricesaponin G2 | 31.46 | C42H62O17 | 837 [M-H]- | 351,113 |
| ( |
| 27 | Psoralen | 32.23 | C11 H6 O3 | 186 [M + H]+ | 187.03, 131.04 |
| ( |
| 28 | Ginsenoside Rb1 | 33.90 | C54H92O23 | 1,107.59 [M-2H]2- | 945.54, 783.48, 621.43 |
| ( |
| 29 | Pimpinellin | 34.20 | C13H10O5 | 247 [M + H]+ | 231,217,203,186,176 |
| ( |
| 30 | Gypenoside XVII | 34.27 | C48H82O18 | 991 [M-H]- | 945.54, 783.48, 621.43 |
| ( |
| 31 | Isoliquiritigenin | 34.96 | C15H12O4 | 257 [M + H]+ | 147, 137 |
| ( |
| 32 | Glycyrrhizic acid | 34.97 | C42H62 O16 | 821 [M-H]- | 645, 351 |
| ( |
| 33 | Licochalcone A | 39.42 | C21H22O4 | 339 [M + H]+ | 297, 121 |
| ( |
| 34 | Z-Ligustilide | 41.13 | C12H14O2 | 232.13 [M + ACN + H]+ | 191, 173 |
| ( |
MW, molecular weight, C7DG, calycosin-7-O-β-D-glucoside.
Active compounds of the Buxue Tongluo Pill.
| Id | Molid | Name | Structure |
|---|---|---|---|
| DG1 | MOL000414 | Caffeic acid |
|
| DG2 | MOL004781 | Pimpinellin |
|
| DG3 | MOL002122 | Z-Ligustilide |
|
| DG4 | MOL000360 | Ferulic acid |
|
| DG5 | MOL001955 | Chlorogenic acid |
|
| DG6 | MOL000219 | Benzoic acid |
|
| HQ1 | MOL001788 | Adenine |
|
| HQ2 | MOL000391 | Ononin |
|
| HQ3 | MOL000510 | Biochanin A |
|
| HQ4 | MOL000392 | Formononetin |
|
| HQ5 | MOL000842 | Sucrose |
|
| HQ6 | MOL009290 | Calycosin-7-O-β-D-glucoside |
|
| HQ7 | MOL000429 | Asparagine |
|
| HQ8 | MOL000390 | Daidzein |
|
| DL1 | MOL000346 | Succinic acid |
|
| DL2 | MOL001831 | Hypoxanthine |
|
| DL3 | MOL000054 |
|
|
| DL4 | MOL000421 | Nicotinic acid |
|
| DL5 | MOL001757 | Guanine |
|
| DL6 | MOL002687 | Guanosine |
|
| DL7 | MOL000041 | Phenylalanine |
|
| DL8 | MOL001780 | Tryptophan |
|
| DL9 | MOL001788 | Adenine |
|
| GC1 | MOL004903 | Liquiritin |
|
| GC2 | MOL001789 | Isoliquiritigenin |
|
| GC3 | MOL004951 | Isoliquiritin |
|
| GC4 | MOL004876 | Glycyrrhizic acid |
|
| GC5 | MOL000497 | Licochalcone A |
|
| GC6 | MOL004892 | Licoricesaponin G2 |
|
| SQ1 | MOL000414 | Caffeic acid |
|
| SQ2 | MOL004549 | 3-Coumaric acid |
|
| SQ3 | MOL001950 | Psoralen |
|
| SQ4 | MOL007495 | Gypenoside XVII |
|
| SQ5 | MOL007476 | Ginsenoside Rb1 |
|
| SQ6 | MOL005338 | Ginsenoside Re |
|
FIGURE 2Total ion current diagram of BTP with positive (upper) and negative modes (lower).
Functional enrichment of the core targets of BTP-DEGs.
| Term | Category | Count |
| Gene ratio |
|---|---|---|---|---|
| KEGG | PI3K-Akt signaling pathway | 9 | 2.982E-13 | 52.94117647 |
| Prostate cancer | 5 | 1.505E-09 | 29.41176471 | |
| Pathways in cancer | 7 | 1.745E-09 | 41.17647059 | |
| Cell cycle | 5 | 9.05E-09 | 29.41176471 | |
| Estrogen signaling pathway | 4 | 3.169E-07 | 23.52941176 | |
| Protein processing in endoplasmic reticulum | 4 | 2.61E-06 | 23.52941176 | |
| Hepatitis C | 4 | 2.802E-06 | 23.52941176 | |
| Proteoglycans in cancer | 4 | 5.796E-06 | 23.52941176 | |
| Central carbon metabolism in cancer | 3 | 7.797E-06 | 17.64705882 | |
| Small cell lung cancer | 3 | 1.689E-05 | 17.64705882 | |
| Progesterone-mediated oocyte maturation | 3 | 2.521E-05 | 17.64705882 | |
| Endocrine resistance | 3 | 2.521E-05 | 17.64705882 | |
| Oocyte meiosis | 3 | 5.416E-05 | 17.64705882 | |
| Fluid shear stress and atherosclerosis | 3 | 8.104E-05 | 17.64705882 | |
| Breast cancer | 3 | 8.447E-05 | 17.64705882 | |
| GO BP | DNA repair | 8 | 5.631E-10 | |
| cell cycle phase transition | 8 | 1.399E-09 | ||
| regulation of cell cycle phase transition | 7 | 6.522E-09 | ||
| regulation of the cell cycle process | 8 | 7.122E-09 | ||
| G1/S transition of the mitotic cell cycle | 6 | 9.284E-09 | ||
| cell cycle G1/S phase transition | 6 | 1.498E-08 | ||
| mitotic cell cycle phase transition | 7 | 2.936E-08 | ||
| positive regulation of the cell cycle | 6 | 7.962E-08 | ||
| DNA biosynthetic process | 5 | 9.436E-08 | ||
| response to the topologically incorrect protein | 5 | 1.149E-07 | ||
| protein insertion into the membrane | 4 | 1.196E-07 | ||
| proteasome-mediated ubiquitin-dependent protein catabolic process | 6 | 1.243E-07 | ||
| regulation of mitotic cell cycle phase transition | 6 | 1.484E-07 | ||
| regulation of cell cycle G2/M phase transition | 5 | 1.558E-07 | ||
| developmental growth involved in morphogenesis | 5 | 1.782E-07 | ||
| GO MF | ubiquitin protein ligase binding | 9 | 2.855E-14 | |
| ubiquitin-like protein ligase binding | 9 | 5.039E-14 | ||
| nitric-oxide synthase regulator activity | 4 | 1.142E-11 | ||
| disordered domain specific binding | 4 | 4.166E-09 | ||
| Kinase binding | 8 | 4.315E-09 | ||
| protein kinase binding | 7 | 5.903E-08 | ||
| protein domain specific binding | 7 | 8.076E-08 | ||
| Protease binding | 4 | 1.015E-06 | ||
| cell adhesion molecule binding | 5 | 1.313E-05 | ||
| histone deacetylase binding | 3 | 4.105E-05 | ||
| unfolded protein binding | 3 | 4.912E-05 | ||
| integrin binding | 3 | 8.104E-05 | ||
| protein phosphatase binding | 3 | 9.162E-05 | ||
| Phosphatase binding | 3 | 0.0002008 | ||
| chromatin binding | 4 | 0.0002956 | ||
| GO CC | vesicle lumen | 5 | 1.147E-06 | |
| melanosome | 3 | 3.392E-05 | ||
| pigment granule | 3 | 3.392E-05 | ||
| secretory granule lumen | 4 | 3.55E-05 | ||
| cytoplasmic vesicle lumen | 4 | 3.725E-05 | ||
| perinuclear region of the cytoplasm | 5 | 5.163E-05 | ||
| ficolin-1-rich granule lumen | 3 | 5.416E-05 | ||
| intracellular protein-containing complex | 5 | 5.621E-05 | ||
| focal adhesion | 4 | 9.86E-05 | ||
| cell-substrate junction | 4 | 0.0001051 | ||
| growth cone | 3 | 0.0001582 | ||
| neuronal cell body | 4 | 0.0001585 | ||
| site of polarized growth | 3 | 0.0001744 | ||
| ficolin-1-rich granule | 3 | 0.0001772 | ||
| protein-DNA complex | 3 | 0.0002502 |
FIGURE 6Osteoclastogenesis with TRAP staining (A) and bone resorption assay (B).
FIGURE 8BTP regulates apoptotic proteins in osteoclasts. (A) Caspase-3, Bcl-2, and Bax (B) Akt and PI3K in osteoclasts. (C) Akt/p-Akt expressions in cells (× 400), p-Akt (green) and Akt (red).
FIGURE 7BTP induces cell apoptosis (A) and decreases MMP (B) in osteoclasts (× 400).